Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03633318 · ClinicalTrials.gov registry record
Establishing Muscle Impedance Parameters With Electrical Impedance Myography
A clinical trial of Inclusion Body Myositis and IBM, sponsored by Yale University.
- Completed
- Registry status
- 31
- Enrollment target
- 1
- Study location
NCT03633318: Completed study of Inclusion Body Myositis and IBM, sponsored by Yale University.
NCT03633318 is a study of Inclusion Body Myositis and IBM that has completed, run by Yale University. The registered enrollment target is 31 participants, below the 233-participant average among 10 other Inclusion Body Myositis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03633318, a study of Inclusion Body Myositis and IBM, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to assess the changes in the impedance parameters of muscles in inclusion body myositis (IBM) through electrical impedance myography (EIM), an emerging non-invasive electrodiagnostic technology. Muscle impedance parameters can potentially serve as an objective biomarker reflecting disease progression and severity.
Primary Outcome
Physical functioning in daily life will be measured using the IBM-Functional rating scale (IBM-FRS). IBM-FRS will be obtained for both IBM participants and healthy controls.
Conditions Studied
Interventions
- DEVICE electrical impedance myography (EIM)
Study Locations (1)
Connecticut
- Yale Physicians Building - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2019-06-30 |
What the finished NCT03633318 record still lists
NCT03633318 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 233-participant average among 10 other Inclusion Body Myositis trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Inclusion Body Myositis appearing as the primary indexed condition, and to 1 intervention - of which electrical impedance myography (EIM) is the first listed.
NCT03633318 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03633318 about?
NCT03633318 is a clinical study titled "Establishing Muscle Impedance Parameters With Electrical Impedance Myography". The primary aim of this study is to assess the changes in the impedance parameters of muscles in inclusion body myositis (IBM) through electrical impedance myography (EIM), an emerging non-invasive electrodiagnostic technology. Muscle impedance parameters can potentially serve as an objective biomar...
What is the current status of trial NCT03633318?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2018-06-19. Estimated completion is 2019-06-30.
What conditions does trial NCT03633318 study?
This clinical trial studies the following conditions: Inclusion Body Myositis, IBM.
What interventions are being tested in trial NCT03633318?
The interventions under investigation include: electrical impedance myography (EIM) (DEVICE).
Who is sponsoring clinical trial NCT03633318?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03633318 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inclusion Body Myositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03633318's enrollment target sits among peer trials
31 6th of 10 higher than 5 of 10 other Inclusion Body Myositis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inclusion Body Myositis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Adult and Juvenile Myositis
RECRUITING
-
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
RECRUITING
-
Sporadic Inclusion Body Myositis Natural History Study
ACTIVE NOT RECRUITING
-
Phase III Trial of Sirolimus in IBM
ACTIVE NOT RECRUITING · Phase 3
-
Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI